|
| Evidence quality assessment of Chinese patent medicine in the treatment of mycoplasma pneumonia in children： An overview of systematic reviews and Meta-analyses |
| Hits 53 Download times 13 Received:October 18, 2024 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2025.02.09 |
| Key Words
mycoplasma pneumonia;Chinese patent medicine;children;GRADE;PRISMA 2020;ROBIS;AMSTAR 2;reassessment |
| Author Name | Affiliation | E-mail | | YANG Shuo | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin 300381, China | | | CAI Qiuhan | National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin 300381, China
Clinical Trial Center, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China | | | HAN Yaowei | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin 300381, China | | | MA Siqi | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin 300381, China | | | MA Weina | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin 300381, China | | | LIU Xinying | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin 300381, China | | | LI Huanmin | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin 300381, China | | | LI Xinmin | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin 300381, China | tjtcmlxm@163.com |
|
| Abstract
|
| [Objective] This study reevaluated the systematic evaluation/Meta-analysis of Chinese patent medicine for the treatment of pediatric mycoplasma pneumonia，to provide a reference for clinical practice and to promote the improvement of the quality of evidence-based evidence for Chinese medicine interventions. [Methods] A systematic search was performed in eight Chinese and English databases，including CNKI and Cochrane Library，collecting systematic reviews and meta-analyses related to Chinese patent medicine in the treatment of mycoplasma pneumonia in children. The search period was ranging from the establishment of each database to October 30，2023. Two reviewers independently screened literature，extracted data，and utilized the PRISMA 2020 for reporting quality assessment，AMSTAR 2 for methodological quality evaluation，GRADE evidence grading for evidence quality assessment，and ROBIS for bias risk assessment and efficacy evaluation. [Results] AA total of 11 studies were included，encompassing 7 types of Chinese patent medicine. The scores of PRISMA 2020 ranged from 12.5 to 25.0，with an average of 18.86. The evaluation of AMSTAR 2 indicated that 9 items were complete in all items and 2 items had large missing in key items. The evaluation of ROBIS indicated 2 studies at low risk，whi.the rest exhibited varying degrees of bias，resulting in overall suboptimal quality. GRADE assessment revealed evidence quality of included studies ranging from moderate to knockdown. [Conclusion] Current evidence suggests that the efficacy of Chinese patent medicine combined with Western medicines in the treatment of pediatric mycoplasma pneumonia may be better than that of the Western medicine group alone，but the quality of reporting of most studies is flawed，the methodological quality and quality of evidence are generally low，and most of the studies have a high risk of bias，which suggests that they have a poor quality of literature and low credibility of the results，and in the future，there is still a need for more high-quality systematic evaluations/Meta analyses to provide reliable and accurate evidence support for Chinese patent medicine treatment’s effectiveness and safety with reliable and accurate evidence support. |
|
|
|
|
|
|
|
